Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

This comparative effectiveness research compares survival end points and response rates among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib and cabazitaxel using results from 2 phase 3 randomized clinical trials.

Shranjeno v:
Bibliografske podrobnosti
izdano v:JAMA Netw Open
Main Authors: Wallis, Christopher J. D., Klaassen, Zachary, Jackson, William C., Dess, Robert T., Reichert, Zachery R., Sun, Yilun, Spratt, Daniel E.
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2021
Teme:
Research Letter
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8144926/
https://ncbi.nlm.nih.gov/pubmed/34028551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2021.10950
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki